Antiphospholipid syndrome

Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
화요일, 3월 12, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Pregnancy, Administration, Risk, C5, Patient, Corporation, Acquisition, EMA, European Medicines Agency, Woman, Injection site reaction, Research and development, Clinical trial, Workforce, Pharmacokinetics, Safety, Antiphospholipid syndrome, Data, Pharmaceutical industry

The workforce reduction included 19 roles and will be substantially complete by the end of the first quarter of 2024.

Key Points: 
  • The workforce reduction included 19 roles and will be substantially complete by the end of the first quarter of 2024.
  • In November 2023, Rallybio announced preliminary data from the completed multiple dose cohort of the Phase 1 safety and pharmacokinetics (PK) study for RLYB212.
  • Research & Development (R&D) Expenses: R&D expenses were $15.9 million for the fourth quarter of 2023, compared to $10.8 million for the same period in 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $5.2 million for the fourth quarter of 2023, compared to $6.3 million for the same period in 2022.

Lupus Research Alliance Announces Recipients of the Lupus Mechanisms and Targets Award

Retrieved on: 
수요일, 2월 28, 2024
LRA, Engineering, Chronic kidney disease, LMTA, Immune system, Infection, Thrombus, Inflammation, Physician, Kidney disease, Quality of life, Lupus Research Alliance, Colchicine, Lupus, Nephritis, NETS, CD19, Skin, Cell, UV, Risk, Autoantibody, APS, Bacteria, Death, Agent handling, Mortal Kombat, Fibrosis, Clinical trial, Gene, Survival, Disease, Antiphospholipid syndrome, Kidney, SLE, S100A4, Research, DNA, Kidney failure, Vaccine

NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).

Key Points: 
  • NEW YORK, Feb. 28, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to announce the recent recipients of the Lupus Mechanisms and Targets Award (LMTA), whose research will investigate molecular pathways or targets that will lead to new or improved therapies for individuals with systemic lupus erythematosus (SLE).
  • The development of targeted treatments is hindered by an incomplete understanding of lupus and its devastating complications.
  • These seven talented investigators will identify targets for new treatments and test novel therapeutic avenues to revolutionize the field and improve the lives of individuals with lupus.
  • Surgical biopsies of the kidneys are often needed to diagnose lupus nephritis (LN), kidney inflammation caused by lupus that can result in severe and sometimes life-threatening organ damage.

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Retrieved on: 
목요일, 2월 8, 2024
Principal, Kidney disease, Corporate development, Ventricular fibrillation, Therapy, OTC, University, Vitamin K antagonist, Financial management, Antiphospholipid syndrome, ESKD, Patient, Atrial fibrillation, APS, PwC, Intellectual property, VKA, Management

In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin.

Key Points: 
  • In this role, Mr. Cole will be responsible for the Company's manufacturing and supply chain operations, intellectual property, commercialization strategies, and supporting partnering activities for tecarfarin.
  • Mr. Cole brings over 25 years of experience in global pharmaceutical manufacturing and commercial operations, finance, and corporate development to the Company.
  • His experience will serve Cadrenal well as we advance our tecarfarin clinical program and evaluate partnering opportunities," commented Quang Pham, Founder, Chairman and Chief Executive Officer of Cadrenal Therapeutics.
  • "I look forward to leveraging my experience to advance tecarfarin to the market and help those underserved patient groups."

Rallybio Announces Portfolio Prioritization and Provides Corporate Update

Retrieved on: 
화요일, 2월 6, 2024
Cardiology, Biotechnology, Technology, Health, Pharmaceutical, Neurology, Health Technology, Research, Artificial Intelligence, Science, Clinical Trials, Mother, Antiphospholipid syndrome, Caregiver, Patient, EMA, Workforce, Data, Risk, Pregnancy, European Medicines Agency, Corporation, Pharmaceutical industry

Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116.

Key Points: 
  • Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready clinical stage programs, RLYB212 and RLYB116.
  • “Following a thorough review of our business, we have made the decision to prioritize our portfolio.
  • Rallybio expects to provide an update on screening numbers in its full-year earnings release in March 2024.
  • Rallybio continues to expect to complete this manufacturing work and provide an update on the development plan for RLYB116 in the second half of 2024.

Autoimmune Disease and Pregnancy: ISB Study Challenges Prevailing Wisdom, Unveils Nuances

Retrieved on: 
수요일, 1월 31, 2024
Other Health, Research, Consumer, Healthcare Reform, Parenting, Science, Baby, Maternity, COVID-19, Other Science, Health, Diabetes, Public Policy, Government, Multimedia, Multiple sclerosis, Sarcoidosis, ISB, Mother, Health information management, Vasculitis, MD, Preterm birth, Inflammatory bowel disease, Antiphospholipid syndrome, Patient, Rheumatoid arthritis, Spondyloarthropathy, Cohort (statistics), Providence, Lupus, Hypertension, Pregnancy, Autoimmunity, Thought, Risk, Psoriatic arthritis, Psoriasis, Autoimmune disease, Gestational age, Birth control

View the full release here: https://www.businesswire.com/news/home/20240131144327/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240131144327/en/
    In a just-published study in the journal Lancet eClinical Health , researchers at the Institute for Systems Biology (ISB) and Providence showed nuanced pregnancy outcomes for pregnant individuals with autoimmune disease.
  • Each type of autoimmune disease is different, each person has their own medical history, and risk may change over the course of pregnancy.
  • This study highlights the importance of taking comorbidities into consideration,” said ISB Associate Professor Jennifer Hadlock, MD , who led the study.
  • “These results can help reshape discussions surrounding autoimmune disease and pregnancy, and bring fresh perspective to a traditionally understudied area in research,” Hadlock said.

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Retrieved on: 
목요일, 1월 4, 2024
Assistive technology, Conference, NASDAQ Biotechnology Index, Anticoagulant, Partnership, Metabolism, Risk, Death, Biotechnology, Warfarin, Bleeding, Antiphospholipid syndrome, APS, Atrial fibrillation, Phạm, Therapy, ESKD, Stroke, Splenic infarction, Kidney disease, Ventricular fibrillation, Patient, Apixaban, Pharmaceutical industry

"Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."

Key Points: 
  • "Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."
  • To arrange a meeting with management, please contact your Biotech Showcase representative or Lytham Partners at [email protected] .
  • The ceremony will feature healthcare companies within the Nasdaq Biotechnology Index, highlighting them as companies pioneering the future.
  • The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024

Retrieved on: 
목요일, 1월 4, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, General Health, Science, Conference, Geographic atrophy, Food, GMG, Risk, Woman, EMA, Paratriathlon, Data, Injection site reaction, AbCellera, HPP, Antiphospholipid syndrome, European Medicines Agency, Pregnancy, Corporation, DSM-IV codes, C5, Hypophosphatasia, ENPP1, Investment, Webcast, Patient, Therapy, Pharmaceutical industry

Rallybio expects to initiate its Phase 2 dose confirmation study for RLYB212 in the second half of 2024.

Key Points: 
  • Rallybio expects to initiate its Phase 2 dose confirmation study for RLYB212 in the second half of 2024.
  • Rallybio expects to complete this manufacturing work and provide an update on the development plan for RLYB116 in the second half of 2024.
  • Rallybio and EyePoint expect to provide an update on this collaboration in the first half of 2024.
  • Rallybio and Exscientia plan to provide an update on the progress of the program in the second half of 2024.

Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Retrieved on: 
수요일, 12월 20, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, GMG, ISR, Aes, Half-life, Incidence, Injection site reaction, Pharmacokinetics, PD, History, Hepatitis, Antiphospholipid syndrome, Corporation, C5, Investment, Webcast, Patient, Safety, Pharmaceutical industry

Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated diseases.

Key Points: 
  • Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated diseases.
  • The Phase 1 MAD study for RLYB116 evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous RLYB116 in healthy participants with multiple dose administration.
  • The reduction in free C5 at 24 hours after the first dose of 100 mg was greater than 99%.
  • “The preliminary results from this Phase 1 multiple ascending dose study of RLYB116 support continued development in patients with gMG,” said Eric Watsky, M.D., RLYB116 Program Lead for Rallybio.

A High-Risk Antiphospholipid Antibody Profile Matters in Pediatric Patients with Antiphospholipid Syndrome

Retrieved on: 
일요일, 11월 12, 2023
Medicine, Research, Artery, SAN, Immune system, Antiphospholipid syndrome, Weill Cornell Medicine, Woman, Risk, ACL, Hospital, Hospital for Special Surgery, Migraine, APS, Patient, APL, American College, American College of Rheumatology, Blood, Diagnosis, MPH, Arthritis, Antibody, Splenic infarction, Repository, ACR, Stroke, Vein, Classification, HSS, Nursing, Medical device, Rheumatology, MD

SAN DIEGO, Nov. 12, 2023 /PRNewswire/ -- A new study by Hospital for Special Surgery (HSS) investigators has found that an initial high-risk antibody profile for antiphospholipid syndrome (APS) tended to remain high in pediatric patients.

Key Points: 
  • SAN DIEGO, Nov. 12, 2023 /PRNewswire/ -- A new study by Hospital for Special Surgery (HSS) investigators has found that an initial high-risk antibody profile for antiphospholipid syndrome (APS) tended to remain high in pediatric patients.
  • "Our study reveals that an initial high-risk antiphospholipid antibody profile is unlikely to be transient in pediatric patients, indicating their risk of serious health problems remains elevated and they should be followed carefully."
  • For patients with symptoms, rheumatologists use three laboratory tests to evaluate the presence of aPL: lupus anticoagulant (LA), anticardiolipin antibody (aCL) and anti-beta-2-glycoprotein-1 antibody (aβ2GPI).
  • "An international effort has been initiated to pool pediatric APS data and ultimately guide the development of classification criteria for pediatric patients."

Thrombophilia Market Projected to Reach $15.9 Billion in 2023 with a CAGR of 7.5%, Driven by Technological Advancements

Retrieved on: 
수요일, 7월 26, 2023
Benchmark, Warfarin, Kidney failure, Heparin, Antiphospholipid syndrome, Vein, Arena Pharmaceuticals, Stroke, Agriculture, COVID-19, Splenic infarction, Pfizer, Artery, Embolism, Hospital, Risk, Rivaroxaban, America's Health Rankings, Growth, Ageing, Novartis, Vaccine, Pharmaceutical industry, Thrombophilia

This report provides strategists, marketers, and senior management with critical information needed to assess the Thrombophilia market.

Key Points: 
  • This report provides strategists, marketers, and senior management with critical information needed to assess the Thrombophilia market.
  • The market is projected to grow from $14.79 billion in 2022 to $15.90 billion in 2023, with a compound annual growth rate (CAGR) of 7.5%.
  • Furthermore, the market is expected to reach $20.87 billion by 2027, with a CAGR of 7.0%.
  • Technological advancements are a key trend in the Thrombophilia market, with major companies focusing on developing innovative technologies to sustain their market position.